Idexx Laboratories (IDXX) Receivables - Net (2009 - 2026)

Idexx Laboratories' Receivables - Net history runs 18 years deep, the most recent figure standing at $603.5 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 14.42% year-over-year to $603.5 million; the TTM figure through Mar 2026 stood at $603.5 million (up 14.42% YoY), while the FY2025 annual figure was $552.4 million, up 16.64% from the prior year.
• Receivables - Net for Q1 2026 stood at $603.5 million, up from $312.7 million in the prior quarter.
• The five-year high for Receivables - Net was $603.5 million in Q1 2026, with the low at $190.8 million in Q4 2022.
• The 5-year median for Receivables - Net is $461.9 million (2023), against an average of $459.3 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net sank 48.2% in 2022, then jumped 139.75% in 2023.
• Idexx Laboratories' Receivables - Net stood at $190.8 million in 2022, then surged by 139.75% to $457.4 million in 2023, then climbed by 3.53% to $473.6 million in 2024, then plunged by 33.97% to $312.7 million in 2025, then surged by 93.01% to $603.5 million in 2026.
• Business Quant data shows IDXX's Receivables - Net at $603.5 million in Q1 2026, $312.7 million in Q4 2025, and $566.9 million in Q3 2025.